Post-Brexit European Clinical Supply Solutions to be Discussed by Catalent at Upcoming Forum
SOMERSET, N.J. – August 11, 2020 — Catalent, a global leader in clinical supply services, today announced that Paul Ingram, Ph.D., Global Director, Strategic Development and Innovation, will present at the upcoming conference, ‘Clinical Trial Supply Forum’, which takes place virtually on Aug. 25-26, 2020.
Dr. Ingram’s presentation, titled, “Beyond Brexit: What Now for Clinical Supply Services Across Europe?“, will take place on Wednesday, Aug. 26, at 2:40 p.m. BST. While the U.K. is no longer a member of the European Union, it remains part of the EU’s Single Market and Customs Union until the end of the transition period, on December 31, 2020. Dr. Ingram’s presentation will explore the potential impact of the U.K. no longer participating in the EU’s Single Market and Customs Union on the clinical supply chain, and discuss strategic options for managing clinical supplies across the U.K. and continental Europe from the beginning of 2021 and beyond.
During his 25-year career, Dr. Ingram’s work has focused on medical devices and pharmaceutical research and development. He has over 15 years of experience in clinical supplies, working in both Phase 1 unit manufacturing suites and trial supplies service companies, including Quintiles (Aptuit), Fisher Clinical and, since 2011, Catalent. Dr. Ingram obtained his doctorate in pharmaceutical development from Strathclyde University in Glasgow, U.K.
For further information, please visit: https://www.clinical.catalent.com/events/clinical-trial-supply-online-2020/
ABOUT CATALENT CLINICAL SUPPLY SERVICES
Catalent is a global leader in clinical supply services, with comprehensive and flexible solutions for small molecules, biologics, and cell and gene therapies and integrated solutions to accelerate speed to clinic. Catalent offers a full range services including clinical supply management, comprehensive packaging solutions, comparator sourcing, cold chain storage and global distribution and specialized supply chain services including direct-to-patient and demand-led supply. With nine GMP clinical packaging facilities and over 50 strategically located depots on six continents combined with more than 25 years’ experience across thousands of studies in more than 80 countries, Catalent has the comprehensive services, global scale and expertise necessary to reliably supply clinical trials of all sizes and complexity anywhere in the world.
Catalent is the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. With over 85 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable global clinical and commercial product supply. Catalent employs over 13,500 people, including approximately 2,400 scientists and technicians, at more than 40 facilities, and in fiscal year 2019 generated over $2.5 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey. For more information, visit www.catalent.com